The Role of Nitric Oxide Related Therapeutics in the Treatment of Cardiovascular Pathologies

Mehmet Kürşat Derici; Emine Demirel Yılmaz

doi:10.5152/EurJTher.2018.344

Authors

Mehmet Kürşat Derici Department of Medical Pharmacology, Kırıkkale University, School of Medicine, Kırıkkale https://orcid.org/0000-0002-8260-7492
Emine Demirel Yılmaz Department of Medical Pharmacology, Ankara University, School of Medicine, Ankara

DOI:

https://doi.org/10.5152/EurJTher.2018.344

Keywords:

Heart, nitric oxide, multiple roles, mechanism, therapeutic implication

Abstract

The heart is a bio pump responsible for the provision of oxygen and nutrients to all body cells. It plays a vital role in the survival of the organism. The essential function of the heart is performed through the close interaction of the cardiac myocytes with the endocardial and capillary endothelial cells. The endothelium releases nitric oxide (NO) and modulates several physiological and pathological processes. The cardiac myocyte is also capable of NO production. Although the effect of NO on cardiac responses has been examined, data regarding the effect of NO on the heart remain controversial. The discrepancies in studies can be explained by several factors, such as different animal species, preparation, redox status, and NO concentration. However, an increasing interest in the role of NO has generated significant progress in the investigation of NO-based therapies. In this review, first, the general properties of NO are described as well as the physiological functions and pathological role in the heart. Then, an evaluation is made of several important NO-related treatment options, such as NO donors, NO synthase inhibitors, phosphodiesterase inhibitors, and soluble guanylate cyclase stimulators/activators. A summary is also given of NO-based drug candidates planned for use in clinical trials in the near future.

Metrics

Metrics Loading ...

References

Moncada S, Palmer RMJ, Higgs EA. Nitric Oxide: Physiology pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42.

Daiber A, Wenzel P, Oelze M, Münzel T. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol 2008; 97: 12-20.

Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro L. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 1979; 5: 211-24.

Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 27; 288: 373-76.

Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987; 61: 866-79.

Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012; 33: 829- 33.

Lundberg JO, Weitzberg E, Cole JA, Benjamin N. Nitrate, bacteria and human health. Nat Rev Microbiol 2004; 2: 593-602.

Gago B, Lundberg JO, Barbosa RM, Laranjinha J. Red wine-dependent reduction of nitrite to nitric oxide in the stomach. Free Radic Biol Med 2007; 43: 1233-42.

Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, et al. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med 2008; 45: 18-31.

Takimoto E. Cyclic GMP-dependent signaling in cardiac myocytes. Circ J 2012; 76: 1819-25.

Cipak Gasparovic A, Zarkovic N, Zarkovic K, Semen K, Kaminskyy D, Yelisyeyeva O, et al. Biomarkers of oxidative and nitro-oxidative stress: conventional and novel approaches. Br J Pharmacol 2017; 174: 1771-83.

Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y, Ali F. Atherosclerotic cardiovascular disease: a review of initiators and protective factors. Inflammopharmacology 2016; 24: 1-10.

Wolhuter K, Eaton P. How widespread is stable protein S-nitrosylation as an end-effector of protein regulation? Free Radic Biol Med 2017; 109: 156-66.

Zhang M, Shah AM. ROS signalling between endothelial cells and cardiac cells. Cardiovasc Res 2014; 102: 249-57.

Brutsaert DL, De Keulenaer GW, Fransen P, Mohan P, Kaluza GL, Andries LJ, et al. The cardiac endothelium: functional morphology, development, and physiology. Prog Cardiovasc Dis 1996; 39: 239-62.

Zhang M, Shah AM. ROS signalling between endothelial cells and cardiac cells. Cardiovasc Res 2014; 102: 249-57.

Zaobornyj T, Ghafourifar P. Strategic localization of heart mitochondrial NOS: a review of the evidence. Am J Physiol Heart Circ Physiol 2012; 303: H1283-93.

Wyeth RP, Temma K, Seifen E, Kennedy RH. Negative inotropic actions of nitric oxide require high doses in rat cardiac muscle. Pflugers Arch 1996; 432: 678-84.

Kojda G, Kottenberg K, Nix P, Schlüter KD, Piper HM, Noack E. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res 1996; 78: 91-101.

Derici K, Samsar U, Demirel-Yilmaz E. Nitric oxide effects depend on different mechanisms in different regions of the rat heart. Heart Vessels 2012; 27: 89-97.

Demirel-Yilmaz E, Cenik B, Ozcan G, Derici MK. Various phosphodiesterase activities in different regions of the heart alter the cardiac effects of nitric oxide. J Cardiovasc Pharmacol 2012; 60: 283-92.

Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ. Activation of distinct cAMP-dependent and cGMPdependent pathways by nitric oxide in cardiac myocytes. Circ Res 1999; 84: 1020-31.

Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phos- phodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011; 91: 651-90.

Chowdhary S, Harrington D, Bonser RS, Coote JH, Townend JN. Chronotropic effects of nitric oxide in the denervated human heart. J Physiol 2002; 541: 645-51.

Kapelko VI. Redox control of cardiac rhythm. Biochemistry (Mosc) 2012; 77: 1248-57.

Levy AS, Chung JC, Kroetsch JT, Rush JW. Nitric oxide and coronary vascular endothelium adaptations in hypertension. Vasc Health Risk Manag 2009; 5: 1075-87.

Ingram DG, Newcomer SC, Price EM, Eklund KE, McAllister RM, Laughlin MH. Chronic nitric oxide synthase inhibition blunts endothelium-dependent function of conduit coronary arteries, not arterioles. Am J Physiol Heart Circ Physiol 2007; 292: H2798-808.

Zhao X, Lu X, Feng Q. Deficiency in endothelial nitric oxide synthase impairs myocardial angiogenesis. Am J Physiol Heart Circ Physiol 2002; 283: H2371-8.

Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol 2018; 100: 1-19.

Soydinc S, Celik A, Demiryurek S, Davutoğlu V, Tarakçıoğlu M, Aksoy M. The relationship between oxidative stress, nitric oxide and coronary artery disease. Eur J Gen Med 2007; 4: 62-6.

Erdmann J, Stark K, Esslinger UB, Rumpf PM, Koesling D, de Wit C, et al. Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature. 2013; 504: 432-6.

Nakata S, Tsutsui M, Shimokawa H, Suda O, Morishita T, Shibata K, et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 2008; 117: 2211-23.

Sun W, Wainwright CL. The role of nitric oxide in modulating ischaemia-induced arrhythmias in rats. J Cardiovasc Pharmacol 1997; 29: 554-62.

Burkard N, Williams T, Czolbe M, Blömer N, Panther F, Link M, et al. Conditional overexpression of neuronal nitric oxide synthase is cardioprotective in ischemia/reperfusion. Circulation 2010; 122: 1588-1603.

Funakoshi H, Kubota T, Kawamura N, Machida Y, Feldman AM, Tsutsui H, et al. Disruption of inducible nitric oxide synthase improves beta-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. Circ Res 2002; 90: 959-65.

Simon JN, Duglan D, Casadei B, Carnicer R. Nitric oxide synthase regulation of cardiac excitation contraction coupling in health and disease. J Mol Cell Cardiol 2014; 73: 80-91.

Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 2002; 106: 2854-8.

Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS. Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep 2007; 59: 715-20.

Shin T, Tanuma N, Kim S, Jin J, Moon C, Kim K, et al. An inhibitor of inducible nitric oxide synthase ameliorates experimental autoimmune myocarditis in Lewis rats. J Neuroimmunol 1998; 92: 133-8.

Benedetto M, Romano R, Baca G, Sarridou D, Fischer A, Simon A, et al. Inhaled nitric oxide in cardiac surgery: Evidence or tradition? Nitric Oxide 2015; 49: 67-79.

Ozçelikay AT, Tay A, Güner S, Taşyaran V, Yildizoğlu-Ari N, Dinçer UD, et al. Reversal effects of L-arginine treatment on blood pressure and vascular responsiveness of streptozotocin-diabetic rats. Pharmacol Res 2000; 41: 201-9.

Wang PG, Xian M, Tang X, Wu X, Wen Z, Cai T, et al. Nitric Oxide Donors: Chemical Activities and Biological Applications. Chem Rev 2002; 102: 1091-134.

Lam CF, Sviri S, Ilett KF, van Heerden PV. Inhaled diazeniumdiolates (NONOates) as selective pulmonary vasodilators. Expert Opin Investig Drugs 2002; 11: 897-909.

Kim-Shapiro DB, Gladwin MT. Mechanisms of nitrite bioactivation. Nitric Oxide 2014; 38: 58-68.

Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov 2015; 14: 623-41.

Mutchler SM, Straub AC. Compartmentalized nitric oxide signaling in the resistance vasculature. Nitric Oxide 2015; 49: 8-15.

Kotera J, Mochida H, Inoue H, Noto T, Fujishige K, Sasaki T, et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol 2012; 188: 668-74.

Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011; 123: 2263-73.

Quinn JF, Whittaker MR, Davis TP. Delivering Nitric Oxide with Nanoparticles. J. Control Release 2015; 205: 190-205.

Ye S, Yang W, Wang Y, Ou W, Ma Q, Yu C, et al. Cationic liposome- mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer. Int J Mol Med 2013; 31: 33-42.